Granules Pharmaceuticals gets USFDA nod for Colchicine tablets
Granules India on Thursday said its wholly owned foreign arm has received US health regulator's approval for Colchicine tablets, used in the treatmen06-02-2020
06-02-2020
Granules India Ltd - 532482 - Granules Pharmaceuticals, Inc. Received US FDA Approval For Colchicine Tablets - Revised Notification
Granules Pharmaceuticals, Inc. received US FDA approval for Colchicine Tablets - Revised Notification06-02-2020
Granules India Ltd - 532482 - Granules Pharmaceuticals, Inc. Received US FDA Approval For Colchicine Tablets
Granules Pharmaceuticals, Inc. received US FDA approval for Colchicine Tablets06-02-2020
Granules India gets USFDA nod for Valganciclovir hydrochloride oral solution
Drug firm Granules India Ltd on Wednesday said its foreign arm has received approval from the US health regulator for Valganciclovir hydrochloride o05-02-2020
GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of the Investor Meeting05-02-2020
Granules India Ltd - 532482 - Granules Pharmaceuticals, Inc. Received US FDA Approval For Valganciclovir Hydrochloride For Oral Solution
Granules Pharmaceuticals, Inc. received US FDA approval for Valganciclovir Hydrochloride for Oral Solution05-02-2020
Granules India divests entire stake in Granules-Biocause Pharmaceutical
Granules India Ltd on Tuesday said it has divested its entire stake in Granules-Biocause Pharmaceutical Co Limited, a joint venture company located i04-02-2020
GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of the Conference call with the Investors04-02-2020
GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Updates on Joint Venture
Update on sale of Company's Stake in Granules-Biocause Pharmaceutical Co. Limited,Joint Venture Company.04-02-2020
Earnings Call Transcript - Q3FY20 for Granules India
Earnings Call Transcript of Discussion between Management and Analysts of Q3FY20 Performance Opening Remarks I am very happy to announce that we are continuing our anticipated growth plans and reap the benefits of our recent investments. Our continued performance validates our growth strategy and the trust that you and other stakeholders had placed on us. I would like to mention a few highlights during the quarter in the discussion. We have started conservatively expensing out total R&D; spends including the filing fees for ANDAs and DMFs starting from Q3. As you all know, the future growth of the company will be driven by the new DMFs and ANDAs, which we file and get approved. During this quarter, we have the expense of a total amount of 22.79 Crores. However, the past spend on R&D; will be capitalized as and when we get approval and certain ANDAs that we feel may not have great potential will be amortized in a very accelerated way from time-to-time. One such example is in this quarter, one of the ANDAs that was recently approved OXY/APAP, which is an opioid product, we felt there was a certain level of uncertainty due to taxes being imposed in certain states on suppliers and wholesalers and due to this we decided to amortize the entire spend on this ANDA, which amounts to $1.2 million. Number two of the highlight is we are expecting a little more than 200 Crores net of TDS from the sale of both our JVs, and the Board had decided to reward the shareholders and approved a buyback of shares of the company at a price of Rs.200 per share and had earmarked an amount of 250 Crores net of the buyback tax for this purpose. Click pdf to read full transcript01-02-2020